Longevity InTime BioTech
Longevity InTime: Developing real-time biometric tech for early disease diagnosis and cure.
Founded
2018Longevity InTime: Developing real-time biometric tech for early disease diagnosis and cure.
Founded in 2018, Longevity InTime BioTech aims to revolutionize healthcare through the development of real-time biometric technologies for early disease diagnosis and treatment. The company's core mission is to extend active lifespans by enabling early-stage prediction and prevention of severe diseases. Utilizing artificial intelligence and big data from evidence-based clinical trials, Longevity InTime offers innovative solutions that empower individuals to monitor their health and take proactive measures.
Notable affiliated individuals include leading scientists and AI experts who contribute to the company's cutting-edge research and development. Longevity InTime has garnered attention from prominent investors in the biotech sector, reflecting confidence in its potential. Key achievements include successful clinical trials and the integration of advanced AI algorithms for accurate health monitoring. The company's impact lies in its ability to provide early diagnosis, which can significantly improve health outcomes and quality of life.
Companies similar to Longevity InTime BioTech include BioAI Health, BioTrillion, Biometry and Regenerative Bio.
Longevity InTime BioTech was founded in 2018.
Longevity InTime BioTech's headquarters is located in Wilmington, DE, US.
Longevity InTime BioTech's most recent funding round was for $100k (USD) in January 2020.
As of Jan 22, 2020, Longevity InTime BioTech has disclosed funding of $2.4M (USD). Undisclosed round amounts are excluded.
Longevity InTime BioTech has 75 employees as of Feb 4, 2024.
Regenerative Bio
regen-bio.us
